Effects of the Vasoactive Intestinal Peptide (VIP) and Related Peptides on Glioblastoma Cell Growth in Vitro

Journal of Molecular Neuroscience

Volumn 21, Issue 2, 2003, Pages 91-102

  Dufes, Christine ^a   Alleaume, Céline ^a   Montoni, Alicia ^a   Olivier, Jean Christophe ^a   Muller, Jean Marc ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

C6 glioblastoma; Cancer; Cell growth; Vasoactive intestinal peptide (VIP); VIP analog; VIP antagonist

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROTENSIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOASSAY; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; GLIOBLASTOMA; GROWTH HORMONE RELEASE; GROWTH RATE; GROWTH STIMULATION; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BINDING, COMPETITIVE; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLIOBLASTOMA; GROWTH HORMONE-RELEASING HORMONE; NEUROPEPTIDES; NEUROTENSIN; PEPTIDE PHI; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RATS; RECEPTORS, CELL SURFACE; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA;

EID: 0242637620     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:21:2:91     Document Type: Article

References (47)

1. Ammirati M., Vick N., Liao Y. L., Ciric I., and Mikhael M. (1987) Effects of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplasic astrocytomas. Neurosurgery 21, 201-206.
2. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity dependent neuroprotective peptide. J. Neurochem. 72(3), 1283-1293.
3. Bassan M., Zamostiano R., Giladi E., Davidson A., Wollman Y., Pitman J., et al. (1998) The identification of secreted heat shock 60-like protein from rat glial cells and a human neuroblastoma cell line. Neurosci. Lett. 250(1), 37-40.
4. Bateman D. E., McDermott J. R., Perry R. H., Dimaline R., Biggins J. A., and Edwardson J. A. (1986) Neuropeptides in gliomas: identification of somatostatin 14 in a medulloblastoma. J. Neurol. Neurosurg. Psychiatry 49(9), 1074-1076.
5. Benda P., Lightbody J., Sato G., Levine L., and Sweet W. (1968) Differentiated rat cell strain in tissue culture. Science 161, 370-371.
6. Bohnen N. I., Radhakrishnan K., O'Neil B. P., and Kurland L. T. (1997) Descriptive and analytic epidemiology of brain tumors, in Cancer of the Nervous System, Black, P. M. and Loeffler, J. S., eds., Blackwell Scientific, Cambridge, MA, pp. 3-24.
7. Brenneman D. E., Glazner G., Hill J. M., Hauser J., Davidson A., and Gozes I. (1998) VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Ann. NY Acad. Sci. 865, 207-212.
8. Brenneman D. E. and Gozes I. (1996) A femtomolar-acting neuroprotectice peptide. J. Clin. Invest. 97(10), 2299-2307.
9. Brenneman D. E., Neale E. A., Foster G. A., D'Autremont S., and Westbrook G. L. (1987) Non neuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J. Cell Biol. 104, 1603-1610.
10. Brenneman D. E., Nicol T., Warren D., and Bowes L. M. (1990) Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J. Neurosci. Res. 25, 386-394.
11. Chneiweiss H., Glowinski J., and Premont J. (1986) Do secretin and vasoactive intestinal peptide have independent receptors on striatal neurons and glial cells in primary culture? J. Neurochem. 47(2), 608-613.
12. Fabry M., Cabrele C., Hocker H., and Beck-Sickinger A. (2000) Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line. Peptides 21, 1885-1893.
13. Gelber E., Granoth R., Fridkin M., Dreznik Z., Brenneman D. E., Moody T. W., and Gozes I. (2001) A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer 92(8), 2172-2180.
14. Gourlet P., Vandermeers A., Vertongen P., Rathe J., De Neef P., Cnudde J., et al. (1997) Development of high-affinity selective VIP1 receptor agonists. Peptides 18(10), 1539-1545.
15. Gozes I. and Brenneman D. E. (1993) Neuropeptides as growth and differentiation factors in general and VIP in particular. J. Mol. Neurosci. 4, 1-9.
16. Gozes I. and Brenneman D. E. (1996) Actvity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J. Mol. Neurosci. 7(4), 235-244.
17. Gozes I., Fridkin M., and Brenneman D. E. (1995) A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Cell. Mol. Neurobiol. 15(6), 675-687.
18. Gozes I., McCune S. K., Jacobson L., Warren D., Moody T. W., Fridkin M., and Brennemen D. E. (1991) An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257, 959-966.
19. Gressens P., Hill J. M., Gozes I., Fridkin M., and Brenneman D. E. (1993) Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362, 155-158.
20. Koh S. W. (1991) Signal transduction through the vasoactive intestinal peptide receptor stimulate phosphorylation of the tyrosine kinase pp60c-src. Biochem. Biophys. Res. Commun. 174, 452-458.
21. Kong L. Y., Marderdrut J. L., Leohn G. H., and Hong J. S. (1999) Reduction of lipopolysaccharide-induced neurotoxicity in mixed cortical neuron-glia cultures by femtomolar concentrations of pituitary adenylate-cyclase activating polypeptide. Neuroscience 91(2), 493-500.
22. Laburthe M., Amiranoff B., Boige N., Rouyer-Fessard C., Tatemoto K., and Moroder L. (1983) Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin. FEBS Lett. 159, 89-92.
23. Lelièvre V., Meunier A. C., Caigneaux E., Falcon J., and Muller J. M. (1998) Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines. Cell. Signal. 10(1), 13-26.
24. Lelièvre V., Pineau N., Du J., Wen C. H., Nguyen T., Janet T., et al. (1998) Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. J. Biol. Chem. 273, 19,685-19,690.
25. Lilling G., Wollman Y., Goldstein M. N., Rubinraut S., Fridkin M., Brenneman D. E., and Gozes I. (1994) Inhibition of human neuroblastoma growth by a specific VIP antagonist. J. Mol. Neurosci. 5, 231-239.
26. 17]-vasoactive intestinal polypeptide. J. Biol. Chem. 261, 5320-5327.
27. Moody T. W., Zia F., Draoui M., Brenneman D. E., Fridkin M., Davidson A., and Gozes I. (1993) A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. USA 90, 4345-4349.
28. Moyer M. P., Aust J. B., Dixon P. S., Levine B. A., and Sirinek K. R. (1985) Glucagon enhances growth of cultured human colorectal cancer cells in vitro. Am. J. Surg. 150, 676-679.
29. Muller J. M., Lelièvre V., Becq-Giraudon L., and Meunier A. C. (1995) VIP as cell-growth and differentiation neuromodulator role in neurodevelopment. Mol. Neurobiol. 10, 115-134.
30. Muller J. M., Lolait S. J., Yu V. C., Sadee W., and Waschek J. A. (1989) Functional receptors in human neuroblastoma subclones that express VIP precursor mRNA and release VIP-like substances. J. Biol. Chem. 264, 3647-3650.
31. Nielsen F. C., Gammeltoft S., Westermark B., and Fahrenkrug J. (1990) High affinity receptors for vasoactive intestinal peptide on a human glioma cell lines. Peptides 11(6), 1225-1231.
32. O'Dorisio S. M., Fleshmann D. J., Qhalman S. J., and O'Dorisio T. M. (1992) Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma. Regul. Pept. 37, 213-226.
33. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D. E., and Gozes I. (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 854(1-2), 257-262.
34. Pavelic K. and Pavelic J. (1980) Glucagon suppressed proliferation rate of mammary aplastic carcinoma in mice. Horm. Metab. Res. 12, 243-246.
35. Pineau N., Lelievre V., Goursaud S., Hilairet S., Waschek J. A., Janet T., and Muller J. M. (2001) The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes. Neuropeptides 35, 1-10.
36. 2 as a GRF antagonist on membranes. Endocrinology 117(5), 1759-1764.
37. Robberecht P., Gourlet P., Vertongen P., and Svoboda M. (1996) Characterization of the VIP receptor from SUP T1 lymphoblasts. Adv. Neuroimmunol. 6, 49-57.
38. Robberecht P., Waelbroeck M., Coy D., De Neef P., Camus J. C., and Christophe J. (1986) Comparative structural requirements of thirty GRF analogs for interaction with GRF and VIP receptors and coupling to adenylate cyclase in rat adenopituitary liver and pancreas. Peptides 7, 53-59.
39. Robberecht P., Woussen-Colle M. C., Vertongen P., De Neef P., Hou X., Salmon I., and Brotchi J. (1994) Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors. Peptides 15(4), 661-665.
40. Said S. I. and Mutt V. (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169, 1217-1218.
41. Sharma A., Walters J., Gozes Y., Fridkin M., Brenneman D., Gozes I., and Moody T. W. (2001) A vasoactive intestinal polypeptide antagonist unhibits the growth of glioblastoma cells. J. Mol. Neurosci. 17(3), 331-339.
42. Vertongen P., Cambry I., Darro F., Kiss R., and Robberecht P. (1996) VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Neuropeptides 30(5), 491-496.
43. Vertongen P., De Clerck P., Fournet J. C., Martelli H., Helardot P., Devalck C., et al. (1997) Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues. Neuropeptides 31(5), 409-413.
44. 2 as a VIP antagonist. Endocrinology 116(6), 2643-2649.
45. Waschek J. A., Dicicco-Bloom E., Lelievre V., Zhou X., and Hu Z. (2000) PACAP action in nervous system development, regeneration and neuroblastoma cell proliferation. Ann. NY Acad. Sci. 921, 129-136.
46. Waschek J. A., Lelievre V., Bravo D. T., Nguyen T., and Muller J. M. (1997) Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines. Peptides 18(6), 835-841.
47. Yu D., Seitz P. K., Selvanayagam P., Rajaraman S., Townsend C. M., and Cooper C. W. (1992) Effects of vasoactive intestinal peptide on adenosine 3′,5′-monophosphate ornithine decarboxylase and cell growth in a human colon cell line. Endocrinology 131, 1188-1194.